Joo-Seop Chung

1.5k total citations
46 papers, 690 citations indexed

About

Joo-Seop Chung is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Joo-Seop Chung has authored 46 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 21 papers in Hematology and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Joo-Seop Chung's work include Lymphoma Diagnosis and Treatment (19 papers), Viral-associated cancers and disorders (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Joo-Seop Chung is often cited by papers focused on Lymphoma Diagnosis and Treatment (19 papers), Viral-associated cancers and disorders (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Joo-Seop Chung collaborates with scholars based in South Korea, United States and South Africa. Joo-Seop Chung's co-authors include Ho‐Jin Shin, Gyeong‐Won Lee, Ho Sup Lee, Young Jin Choi, Sang‐Min Lee, Seong‐Jang Kim, Jong Wook Lee, Je‐Hwan Lee, Jin Seok Kim and Suee Lee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Joo-Seop Chung

46 papers receiving 675 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joo-Seop Chung South Korea	14	310	213	211	200	155	46	690
Charles Ludivico United States	9	111 0.4×	352 1.7×	167 0.8×	268 1.3×	228 1.5×	13	1.0k
Filiz Şen United States	16	278 0.9×	117 0.5×	213 1.0×	124 0.6×	163 1.1×	42	623
Stéphane Chèze France	16	353 1.1×	700 3.3×	157 0.7×	159 0.8×	372 2.4×	46	1.0k
Jean Tayar United States	10	137 0.4×	94 0.4×	453 2.1×	163 0.8×	185 1.2×	30	846
Lorella Orsucci Italy	15	713 2.3×	132 0.6×	356 1.7×	123 0.6×	441 2.8×	45	892
Stanton Goldman United States	16	443 1.4×	102 0.5×	359 1.7×	112 0.6×	124 0.8×	38	1.0k
Ozren Jakšić Croatia	15	234 0.8×	227 1.1×	233 1.1×	273 1.4×	407 2.6×	55	857
Jens Kuhlmann Germany	9	324 1.0×	42 0.2×	220 1.0×	108 0.5×	147 0.9×	13	585
Glen R. Justice United States	15	679 2.2×	547 2.6×	584 2.8×	120 0.6×	480 3.1×	31	1.3k
J. Zeffren United States	14	247 0.8×	71 0.3×	325 1.5×	304 1.5×	101 0.7×	18	772

Countries citing papers authored by Joo-Seop Chung

Since Specialization

Citations

This map shows the geographic impact of Joo-Seop Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joo-Seop Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joo-Seop Chung more than expected).

Fields of papers citing papers by Joo-Seop Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joo-Seop Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joo-Seop Chung. The network helps show where Joo-Seop Chung may publish in the future.

Co-authorship network of co-authors of Joo-Seop Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Joo-Seop Chung. A scholar is included among the top collaborators of Joo-Seop Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joo-Seop Chung. Joo-Seop Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shin, Ho‐Jin, et al.. (2020). Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica. 144(4). 427–437. 8 indexed citations

Kim, Do Young, et al.. (2020). Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. Annals of Hematology. 99(4). 819–828. 2 indexed citations

Chung, Joo-Seop, Ho‐Young Yhim, Sung-Nam Lim, et al.. (2017). Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. Oncotarget. 8(45). 79337–79346. 8 indexed citations

Chung, Joo-Seop, et al.. (2016). Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy. Annals of Hematology. 96(1). 17–23. 15 indexed citations

Lee, Jong Wook, Jun Ho Jang, Je‐Hwan Lee, et al.. (2013). Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. Blood. 122(21). 3720–3720. 1 indexed citations

Lee, Jong Wook, Jun Ho Jang, Jin Seok Kim, et al.. (2013). Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. International Journal of Hematology. 97(6). 749–757. 90 indexed citations

Oh, Minyoung, Joo-Seop Chung, Ho‐Jin Shin, et al.. (2013). Prognostic value of Waldeyer’s ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. International Journal of Hematology. 97(3). 397–402. 10 indexed citations

Chung, Joo-Seop, Sung‐Yong Oh, Gyeong‐Won Lee, et al.. (2010). Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy. Annals of Hematology. 89(10). 985–991. 21 indexed citations

Yang, Deok‐Hwan, Yeo‐Kyeoung Kim, Joo-Seop Chung, et al.. (2010). Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 10(1). 62–67. 12 indexed citations

10.

Lee, Sung Sook, Cheolwon Suh, Bong-Seog Kim, et al.. (2010). Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology. 89(9). 905–912. 16 indexed citations

11.

Chung, Joo-Seop, Young‐Don Joo, Sang‐Min Lee, et al.. (2010). Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients. Acta Haematologica. 124(1). 34–39. 3 indexed citations

12.

Min, Yoo Hong, Hyeoung Joon Kim, Kyoo‐Hyung Lee, et al.. (2010). A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri.. Blood. 116(21). 1125–1125. 1 indexed citations

13.

Koh, Youngil, Dae‐Young Kim, Seung‐Hyun Jung, et al.. (2010). GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. Cancer Genetics and Cytogenetics. 203(2). 215–221. 9 indexed citations

14.

Lee, Ji Hyun, Kyung A Kwon, Suee Lee, et al.. (2010). Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults. The Korean Journal of Hematology. 45(4). 242–242. 2 indexed citations

15.

Eom, Hyeon‐Seok, Yeo‐Kyeoung Kim, Joo-Seop Chung, et al.. (2009). Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology. 89(5). 489–497. 8 indexed citations

16.

Hwang, Sang‐Hyun, et al.. (2009). Quantitation of whole blood Epstein‐Barr virus DNA is useful for assessing treatment response in patients with non‐Hodgkin’s lymphoma. International Journal of Laboratory Hematology. 32(1p1). e106–13. 8 indexed citations

17.

Chung, Joo-Seop, et al.. (2009). Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?. Leukemia Research. 33(11). 1459–1462. 2 indexed citations

18.

Lee, Sung Sook, Cheolwon Suh, Bong-Seog Kim, et al.. (2007). Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dexamethasone (TD) as a Salvage Treatment for Relapsed Multiple Myeloma (MM): Preliminary Analysis of Efficacy and Safety.. Blood. 110(11). 2731–2731. 3 indexed citations

19.

Chae, Y.S., Sang Kyun Sohn, Young Jin Choi, et al.. (2006). Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Journal of Clinical Oncology. 24(18_suppl). 14037–14037. 1 indexed citations

20.

So, C.C, K.F. Wong, Joo-Seop Chung, & Yok‐Lam Kwong. (1999). BCR/ABL Translocation in Adult Acute Lymphoblastic Leukemia. Cancer Genetics and Cytogenetics. 110(1). 19–22. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact